Drug Profile
MG S 2525
Alternative Names: MG-S-2525Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator SMA Therapeutics
- Developer Metagone Biotech
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action MAP3K19 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Bronchiectasis; Idiopathic pulmonary fibrosis
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in Taiwan (PO)
- 06 Dec 2023 Metagone Biotech plans a phase III trial for Bronchiectasis in the fourth quarter of 2023 (Metagone Biotech pipeline, December 2023)
- 06 Dec 2023 Metagone Biotech plans a phase III trial for Idiopathic pulmonary fibrosis in the fourth quarter of 2023 (Metagone Biotech pipeline, December 2023)